Immediate Impact
42 standout
Citing Papers
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
Pre-metastatic niche: formation, characteristics and therapeutic implication
2024 Standout
Works of Patrick Henrick being referenced
Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
2022
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Patrick Henrick | 70 | 31 | 74 | 79 | 11 | 158 | |
| Ndegwa Njuguna | 39 | 60 | 85 | 47 | 8 | 181 | |
| José Antonio Queizán | 94 | 26 | 68 | 54 | 13 | 156 | |
| Heather Ogana | 79 | 23 | 60 | 64 | 15 | 186 | |
| Felix Seyfried | 42 | 22 | 69 | 35 | 15 | 137 | |
| Jared Henderson | 19 | 50 | 36 | 54 | 11 | 125 | |
| Giorgia Chiodin | 49 | 79 | 72 | 35 | 14 | 197 | |
| Sonia Ali | 39 | 33 | 90 | 62 | 11 | 176 | |
| Madelon M.E. de Jong | 124 | 9 | 100 | 80 | 14 | 213 | |
| Tobias Roider | 18 | 34 | 61 | 58 | 18 | 162 | |
| Katherine E. Pendleton | 96 | 13 | 92 | 100 | 11 | 209 |
All Works
Loading papers...